How much revenue did Evotec generate this year?
Evotec has achieved a revenue of 836.9 M EUR this year.
Evotec Revenue 2024
Evotec Revenue
836.9 M EUR
Ticker
EVT.DE
ISIN
DE0005664809
WKN
566480
In 2024, Evotec's sales reached 836.9 M EUR, a 7.1% difference from the 781.43 M EUR sales recorded in the previous year.
The Evotec Revenue history
| YEAR | REVENUE (undefined EUR) | GROSS MARGIN (%) |
|---|---|---|
| 2029e | 1.71 | 10,25 |
| 2028e | 1.49 | 11,74 |
| 2027e | 1.34 | 13,04 |
| 2026e | 1.11 | 15,83 |
| 2025e | 0.96 | 18,30 |
| 2024e | 0.84 | 20,92 |
| 2023 | 0.78 | 22,40 |
| 2022 | 0.75 | 23,16 |
| 2021 | 0.62 | 24,52 |
| 2020 | 0.5 | 25,10 |
| 2019 | 0.45 | 29,77 |
| 2018 | 0.38 | 29,84 |
| 2017 | 0.26 | 31,01 |
| 2016 | 0.16 | 35,59 |
| 2015 | 0.13 | 27,51 |
| 2014 | 0.09 | 32,83 |
| 2013 | 0.09 | 36,32 |
| 2012 | 0.09 | 35,51 |
| 2011 | 0.08 | 43,70 |
| 2010 | 0.06 | 43,94 |
| 2009 | 0.04 | 43,09 |
| 2008 | 0.04 | 44,44 |
| 2007 | 0.03 | 24,32 |
| 2006 | 0.07 | 34,12 |
| 2005 | 0.08 | 36,34 |
| 2004 | 0.07 | 34,25 |
Evotec Revenue, EBIT, Net Income DE0005664809 · 566480
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Evotec, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Evotec from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Evotec’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Evotec. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Evotec’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Evotec’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Evotec’s growth potential.
Evotec Revenue, EBIT and net profit per share
| Date | Evotec Revenue | Evotec EBIT | Evotec Net Income |
|---|---|---|---|
| 2029e | 1.71 B undefined | 0 undefined | 97.54 M undefined |
| 2028e | 1.49 B undefined | 212.29 M undefined | 111.22 M undefined |
| 2027e | 1.34 B undefined | 170.42 M undefined | 84.85 M undefined |
| 2026e | 1.11 B undefined | 94.86 M undefined | 36.04 M undefined |
| 2025e | 956.34 M undefined | 51.67 M undefined | -2.39 M undefined |
| 2024e | 836.9 M undefined | -12.57 M undefined | -85.06 M undefined |
| 2023 | 781.43 M undefined | -42.5 M undefined | -83.91 M undefined |
| 2022 | 751.45 M undefined | 20.85 M undefined | -175.66 M undefined |
| 2021 | 618.03 M undefined | 41.68 M undefined | 215.51 M undefined |
| 2020 | 500.92 M undefined | 51.8 M undefined | 6.28 M undefined |
| 2019 | 446.44 M undefined | 74.51 M undefined | 38.07 M undefined |
| 2018 | 375.41 M undefined | 66.43 M undefined | 84.17 M undefined |
| 2017 | 263.77 M undefined | 37.91 M undefined | 23.48 M undefined |
| 2016 | 164.51 M undefined | 36.75 M undefined | 27.53 M undefined |
| 2015 | 127.68 M undefined | -2.53 M undefined | 16.52 M undefined |
| 2014 | 89.5 M undefined | 2.14 M undefined | -6.98 M undefined |
| 2013 | 85.9 M undefined | 4.1 M undefined | -25.4 M undefined |
| 2012 | 87.3 M undefined | 300,000 undefined | 2.5 M undefined |
| 2011 | 80.1 M undefined | 5.8 M undefined | 6.7 M undefined |
| 2010 | 55.3 M undefined | 1.7 M undefined | 3.3 M undefined |
| 2009 | 42.7 M undefined | -19.6 M undefined | -45.5 M undefined |
| 2008 | 39.6 M undefined | -45.5 M undefined | -78.3 M undefined |
| 2007 | 32.9 M undefined | -49.2 M undefined | -11.2 M undefined |
| 2006 | 67.4 M undefined | -30.8 M undefined | -32.5 M undefined |
| 2005 | 79.8 M undefined | -16.9 M undefined | -33.6 M undefined |
| 2004 | 72.7 M undefined | -21.7 M undefined | -84.2 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 72.7 M EUR | -21.7 M EUR | -84.2 M EUR |
| 2005 | 79.8 M EUR | -16.9 M EUR | -33.6 M EUR |
| 2006 | 67.4 M EUR | -30.8 M EUR | -32.5 M EUR |
| 2007 | 32.9 M EUR | -49.2 M EUR | -11.2 M EUR |
| 2008 | 39.6 M EUR | -45.5 M EUR | -78.3 M EUR |
| 2009 | 42.7 M EUR | -19.6 M EUR | -45.5 M EUR |
| 2010 | 55.3 M EUR | 1.7 M EUR | 3.3 M EUR |
| 2011 | 80.1 M EUR | 5.8 M EUR | 6.7 M EUR |
| 2012 | 87.3 M EUR | 300,000 EUR | 2.5 M EUR |
| 2013 | 85.9 M EUR | 4.1 M EUR | -25.4 M EUR |
| 2014 | 89.5 M EUR | 2.14 M EUR | -6.98 M EUR |
| 2015 | 127.68 M EUR | -2.53 M EUR | 16.52 M EUR |
| 2016 | 164.51 M EUR | 36.75 M EUR | 27.53 M EUR |
| 2017 | 263.77 M EUR | 37.91 M EUR | 23.48 M EUR |
| 2018 | 375.41 M EUR | 66.43 M EUR | 84.17 M EUR |
| 2019 | 446.44 M EUR | 74.51 M EUR | 38.07 M EUR |
| 2020 | 500.92 M EUR | 51.8 M EUR | 6.28 M EUR |
| 2021 | 618.03 M EUR | 41.68 M EUR | 215.51 M EUR |
| 2022 | 751.45 M EUR | 20.85 M EUR | -175.66 M EUR |
| 2023 | 781.43 M EUR | -42.5 M EUR | -83.91 M EUR |
| 2024e | 836.9 M EUR | -12.57 M EUR | -85.06 M EUR |
| 2025e | 956.34 M EUR | 51.67 M EUR | -2.39 M EUR |
| 2026e | 1.11 B EUR | 94.86 M EUR | 36.04 M EUR |
| 2027e | 1.34 B EUR | 170.42 M EUR | 84.85 M EUR |
| 2028e | 1.49 B EUR | 212.29 M EUR | 111.22 M EUR |
| 2029e | 1.71 B EUR | 0 EUR | 97.54 M EUR |
Evotec stock margins DE0005664809 · 566480
The Evotec margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Evotec. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Evotec.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Evotec's sales revenue. A higher gross margin percentage indicates that the Evotec retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Evotec's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Evotec's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Evotec's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Evotec. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Evotec's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Evotec Margin History
| Evotec Gross margin | Evotec Profit margin | Evotec EBIT margin | Evotec Profit margin |
|---|---|---|---|
| 2029e | 22.4 % | 0 % | 5.71 % |
| 2028e | 22.4 % | 14.24 % | 7.46 % |
| 2027e | 22.4 % | 12.7 % | 6.32 % |
| 2026e | 22.4 % | 8.58 % | 3.26 % |
| 2025e | 22.4 % | 5.4 % | -0.25 % |
| 2024e | 22.4 % | -1.5 % | -10.16 % |
| 2023 | 22.4 % | -5.44 % | -10.74 % |
| 2022 | 23.16 % | 2.77 % | -23.38 % |
| 2021 | 24.52 % | 6.74 % | 34.87 % |
| 2020 | 25.1 % | 10.34 % | 1.25 % |
| 2019 | 29.77 % | 16.69 % | 8.53 % |
| 2018 | 29.84 % | 17.69 % | 22.42 % |
| 2017 | 31.01 % | 14.37 % | 8.9 % |
| 2016 | 35.59 % | 22.34 % | 16.73 % |
| 2015 | 27.51 % | -1.98 % | 12.94 % |
| 2014 | 32.83 % | 2.39 % | -7.8 % |
| 2013 | 36.32 % | 4.77 % | -29.57 % |
| 2012 | 35.51 % | 0.34 % | 2.86 % |
| 2011 | 43.7 % | 7.24 % | 8.36 % |
| 2010 | 43.94 % | 3.07 % | 5.97 % |
| 2009 | 43.09 % | -45.9 % | -106.56 % |
| 2008 | 44.44 % | -114.9 % | -197.73 % |
| 2007 | 24.32 % | -149.54 % | -34.04 % |
| 2006 | 34.12 % | -45.7 % | -48.22 % |
| 2005 | 36.34 % | -21.18 % | -42.11 % |
| 2004 | 34.25 % | -29.85 % | -115.82 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 34.25 % | -29.85 % | -115.82 % |
| 2005 | 36.34 % | -21.18 % | -42.11 % |
| 2006 | 34.12 % | -45.7 % | -48.22 % |
| 2007 | 24.32 % | -149.54 % | -34.04 % |
| 2008 | 44.44 % | -114.9 % | -197.73 % |
| 2009 | 43.09 % | -45.9 % | -106.56 % |
| 2010 | 43.94 % | 3.07 % | 5.97 % |
| 2011 | 43.7 % | 7.24 % | 8.36 % |
| 2012 | 35.51 % | 0.34 % | 2.86 % |
| 2013 | 36.32 % | 4.77 % | -29.57 % |
| 2014 | 32.83 % | 2.39 % | -7.8 % |
| 2015 | 27.51 % | -1.98 % | 12.94 % |
| 2016 | 35.59 % | 22.34 % | 16.73 % |
| 2017 | 31.01 % | 14.37 % | 8.9 % |
| 2018 | 29.84 % | 17.69 % | 22.42 % |
| 2019 | 29.77 % | 16.69 % | 8.53 % |
| 2020 | 25.1 % | 10.34 % | 1.25 % |
| 2021 | 24.52 % | 6.74 % | 34.87 % |
| 2022 | 23.16 % | 2.77 % | -23.38 % |
| 2023 | 22.4 % | -5.44 % | -10.74 % |
| 2024e | 22.4 % | -1.5 % | -10.16 % |
| 2025e | 22.4 % | 5.4 % | -0.25 % |
| 2026e | 22.4 % | 8.58 % | 3.26 % |
| 2027e | 22.4 % | 12.7 % | 6.32 % |
| 2028e | 22.4 % | 14.24 % | 7.46 % |
| 2029e | 22.4 % | 0 % | 5.71 % |
Evotec Aktienanalyse
What does Evotec do?
Evotec SE is a biotechnology company based in Hamburg that specializes in the development of drug compounds for the pharmaceutical and biotech industries. The company was founded in 1993 as part of a research project at the University of Hamburg and has since become one of the leading drug discovery and development companies globally. Evotec's business model is based on collaborating with its customers, primarily large pharmaceutical companies, to develop new and innovative drugs. Evotec offers its extensive expertise in drug discovery and acts as a service provider. The company has modern laboratories equipped with state-of-the-art scientific methods and technologies. Customers benefit from the scientists' years of experience and collaboration with renowned academic institutions worldwide. Evotec operates in the Discovery, Development, and Manufacturing segments, providing a wide range of services to its customers. In the Discovery segment, the focus is on identifying drug candidates and preclinical development of drugs using advanced technologies and research methods. In the Development segment, Evotec supports its customers in the planning, execution, and analysis of clinical trials. The close collaboration with customers allows Evotec's scientists to respond quickly and effectively to feedback and requirements. The Manufacturing segment involves the industrial production of drugs. Evotec offers a broad range of products, including both its own and customer-requested drug compounds. One example is the drug DiaPep277 for the treatment of Type 1 diabetes. DiaPep277 was developed by Evotec in collaboration with Israeli company Andromeda Biotech and is now distributed by Teva Pharmaceuticals. Another example is the drug EVT307, which was developed by Evotec in collaboration with pharmaceutical company Boehringer Ingelheim and is currently being tested in Phase II clinical trials for the treatment of schizophrenia. Evotec's success is also based on its expertise in the production of small molecules. Small molecules are drug compounds characterized by their small size and highly specific binding to target proteins. In contrast, the production of large molecules such as antibodies or biologics is more complex and expensive in development due to their size. Evotec's success story continues: In 2019, the company achieved record results, increasing its revenue by 23 percent to 446.4 million euros. The number of employees has also steadily grown in recent years and now exceeds 3,000 employees worldwide. Evotec is considered one of the most successful biotechnology companies in Europe today. Evotec ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Evotec's Sales Figures
The sales figures of Evotec originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Evotec’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Evotec's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Evotec’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Evotec stock
How much was the turnover of the company Evotec compared to the previous year?
The revenue of Evotec has increased by 7.1% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Evotec?
The revenue of Evotec is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Evotec measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Evotec so important for investors?
The revenue of Evotec is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Evotec pay?
Over the past 12 months, Evotec paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Evotec is expected to pay a dividend of 0 EUR.
What is the dividend yield of Evotec?
The current dividend yield of Evotec is .
When does Evotec pay dividends?
Evotec pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Evotec?
Evotec paid dividends every year for the past 0 years.
What is the dividend of Evotec?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Evotec located?
Evotec is assigned to the 'Health' sector.
Wann musste ich die Aktien von Evotec kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Evotec from 10/6/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.
When did Evotec pay the last dividend?
The last dividend was paid out on 10/6/2024.
What was the dividend of Evotec in the year 2023?
In the year 2023, Evotec distributed 0 EUR as dividends.
In which currency does Evotec pay out the dividend?
The dividends of Evotec are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Evotec stock can be added to a savings plan with the following providers: Trade Republic, ING, Scalable Capital and Consorsbank
Andere Kennzahlen von Evotec
Our stock analysis for Evotec Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Evotec Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
